Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial

BACKGROUND: Pradefovir is a liver-targeted prodrug of adefovir, a nucleoside/nucleotide analogue with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30, 45, 60, or 75 mg) versus tenofovir disoproxil fumarate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yanhang, Kong, Fei, Song, Xinwen, Shang, Jia, Yao, Lvfeng, Xia, Jinyu, Peng, Yanzhong, Liu, Weidong, Gong, Huanyu, Mu, Mao, Cui, Hesong, Han, Tao, Chen, Wen, Wu, Xiaolu, Yang, Yongfeng, Yan, Xuebing, Jin, Zhenjing, Wang, Peng, Zhu, Qingjing, Chen, Liang, Zhao, Caiyan, Zhang, Dengke, Jin, Weili, Wang, Daidi, Wen, Xiuhong, Liu, Chunmei, Jia, Jidong, Mao, Qing, Ding, Yanhua, Jin, Xueyuan, Zhang, Zong, Mao, Qianguo, Li, Guangming, Niu, Junqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187326/
https://www.ncbi.nlm.nih.gov/pubmed/34487151
http://dx.doi.org/10.1093/cid/ciab763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187326/
https://www.ncbi.nlm.nih.gov/pubmed/34487151
http://dx.doi.org/10.1093/cid/ciab763

Ejemplares similares